IDEXX Laboratories' second quarter revenue and EPS beat estimates, driven by 10% organic growth in its key diagnostics business.

IDEXX Laboratories reported second quarter 2026 revenue of $1.217 billion, up 10% year-over-year, and EPS of $4.27, an 18% increase. Both top and bottom-line results surpassed analyst expectations, supported by strong performance in the Companion Animal Group (CAG).

Key Highlights

• Companion Animal Group (CAG) Diagnostics recurring revenue grew 10% organically, exceeding analyst expectations and driving overall results.
• Operating margin expanded by 140 basis points year-over-year to 35.0%, supported by strong recurring revenue volume and net price realization.
• IDEXX raised its full-year 2026 outlook, increasing the midpoint of its revenue guidance by $5 million to $4.72 billion and its EPS guidance by $0.14 to a midpoint of $14.82.